Acumen Pharmaceuticals (ABOS) Enterprise Value (2020 - 2026)
Acumen Pharmaceuticals (ABOS) reported Enterprise Value of -$128.0 million for Q1 2026, up 14.18% on a YoY basis from -$112.1 million in Q1 2025, and down 9.53% sequentially from -$116.9 million in Q4 2025.
Acumen Pharmaceuticals (ABOS) Enterprise Value (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 7 years of Enterprise Value data on file, last reported at -$128.0 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 14.18% year-over-year to -$128.0 million; the trailing twelve-month figure through Mar 2026 stood at -$128.0 million (up 14.18% YoY), and the FY2025 full-year result was -$116.9 million, up 31.75% from the prior year.
- Enterprise Value slipped to -$128.0 million in Q1 2026, from -$116.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$116.9 million in Q4 2025 to a low of -$260.5 million in Q2 2024.
- A 5-year average of -$179.3 million and a median of -$177.6 million in 2022 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value tumbled 416.06% in 2022 and soared 44.96% in 2025, its largest moves.
- Tracing ABOS's Enterprise Value over 5 years: stood at -$177.6 million in 2022, then plunged by 36.73% to -$242.8 million in 2023, then climbed by 29.49% to -$171.2 million in 2024, then jumped by 31.75% to -$116.9 million in 2025, then slipped by 9.53% to -$128.0 million in 2026.
- Business Quant data shows ABOS's Enterprise Value at -$128.0 million in Q1 2026, -$116.9 million in Q4 2025, and -$126.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -1.91 Bn |
| 10 | Acumen Pharmaceuticals | 140.98 Mn | 140.98 Mn | - | -128.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.00 Mn |
| Dec 31, 2025 | -116.87 Mn |
| Sep 30, 2025 | -126.61 Mn |
| Jun 30, 2025 | -143.37 Mn |
| Mar 31, 2025 | -149.15 Mn |
| Dec 31, 2024 | -171.23 Mn |
| Sep 30, 2024 | -199.96 Mn |
| Jun 30, 2024 | -260.47 Mn |
| Mar 31, 2024 | -252.51 Mn |
| Dec 31, 2023 | -242.84 Mn |
| Sep 30, 2023 | -215.43 Mn |
| Jun 30, 2023 | -144.88 Mn |
| Mar 31, 2023 | -140.41 Mn |
| Dec 31, 2022 | -177.61 Mn |
| Sep 30, 2022 | -200.19 Mn |
| Jun 30, 2022 | -189.91 Mn |
| Mar 31, 2022 | -189.09 Mn |
| Dec 31, 2021 | -194.24 Mn |
| Sep 30, 2021 | -198.96 Mn |
| Jun 30, 2021 | -36.80 Mn |